Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 11/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17694561 | 0.83 | NOTUM (0.78) | NOTUMKDM4EALDH1A1LMNATLR8 | |
| SCHEMBL6876881 | 0.82 | NOTUM (0.51) | NOTUMKDM4EALDH1A1LMNATLR8 | |
| SCHEMBL6876871 | 0.82 | NOTUM (0.51) | NOTUMKDM4EALDH1A1LMNATLR8 | |
| SCHEMBL2610163 | 0.81 | NOTUM (0.75) | NOTUMKDM4EALDH1A1LMNATLR8 | |
| SCHEMBL27920486 | 0.81 | NOTUM (0.58) | NOTUMKDM4EALDH1A1LMNATLR8 | |
| SCHEMBL1174549 | 0.79 | NOTUM (0.58) | NOTUMKDM4EALDH1A1LMNATLR8 | |
| SCHEMBL6852556 | 0.78 | NOTUM (0.55) | NOTUMKDM4EALDH1A1LMNATLR8 | |
| SCHEMBL6854287 | 0.78 | NOTUM (0.55) | NOTUMKDM4EALDH1A1LMNATLR8 | |
| SCHEMBL19219013 | 0.75 | NPC1 (0.52) | KDM4EALDH1A1TP53MAPTTSHR | |
| SCHEMBL17824500 | 0.75 | NOTUM (0.58) | NOTUMKDM4EALDH1A1LMNATLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3612188-B1 | HETEROBIVALENT LIGANDS SUITABLE FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | T C ISTANBUL MEDIPOL UNIV (TR) | 2023-12-13 | — | — | EP | disclosed |
| EP-3230254-B1 | COMPOSITIONS AND METHODS FOR TREATING DISEASES AND CONDITIONS | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2021-09-22 | — | — | EP | disclosed |
| EP-3230254-B1 | COMPOSITIONS AND METHODS FOR TREATING DISEASES AND CONDITIONS | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2021-09-22 | — | — | EP | disclosed |
| US-11072606-B2 | Compositions and methods for treating diseases and conditions | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-07-27 | — | — | US | disclosed |
| US-11072606-B2 | Compositions and methods for treating diseases and conditions | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-07-27 | — | — | US | disclosed |
| CN-107207407-B | Compositions and methods for treating diseases and disorders | 高等教育联邦系统-匹兹堡大学 | 2020-12-01 | — | — | CN | disclosed |
| US-20200087294-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASES AND CONDITIONS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-03-19 | — | — | US | disclosed |
| US-20200087294-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASES AND CONDITIONS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-03-19 | — | — | US | disclosed |
| US-10487076-B2 | Compositions and methods for treating diseases and conditions | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2019-11-26 | — | — | US | disclosed |
| US-10487076-B2 | Compositions and methods for treating diseases and conditions | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2019-11-26 | — | — | US | disclosed |
| US-20180134693-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASES AND CONDITIONS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180134693-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASES AND CONDITIONS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-05-17 | — | — | US | disclosed |
| EP-3230254-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASES AND CONDITIONS | University of Pittsburgh - Of the Commonwealth System of Higher Education (US) | 2017-10-18 | — | — | EP | disclosed |
| WO-2016094659-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASES AND CONDITIONS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016094659-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASES AND CONDITIONS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-06-16 | — | — | WO | disclosed |
| CN-1585775-A | 6-O-acyl ketolide derivatives of erythromycine useful as antibacterials | ORTHO MCNEIL PHARM INC (US) | 2005-02-23 | — | — | CN | disclosed |
| US-6825170-B2 | ERYTHROMYCIN TYPE MACROLIDE WITH A FUSED OXAZOLONE RING | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-11-30 | — | — | US | disclosed |
| EP-1453847-A1 | 6-O-ACYL KETOLIDE DERIVATIVES OF ERYTHROMYCINE USEFUL AS ANTIBACTERIALS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20030220272-A1 | 6-O-acyl ketolide antibacterials | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-11-27 | — | — | US | disclosed |
| WO-2003050132-A1 | 6-O-ACYL KETOLIDE DERIVATIVES OF ERYTHROMYCINE USEFUL AS ANTIBACTERIALS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11072606-B2 | Compositions and methods for treating diseases and conditions | C1S, SLC10A1, C1R | NOTUM 2174/4885KDM4E 4401/4885ALDH1A1 1803/4885 |
| US-10487076-B2 | Compositions and methods for treating diseases and conditions | C1S, SLC10A1, C1R | NOTUM 2085/4885KDM4E 4400/4885ALDH1A1 1801/4885 |
| US-20030220272-A1 | 6-O-acyl ketolide antibacterials | Q6ZSR9, ACSL6, RPS4Y1 | NOTUM 2862/4885KDM4E 18/4885ALDH1A1 2109/4885 |
| US-20200087294-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASES AND CONDITIONS | C1S, SLC10A1, C1R | NOTUM 2174/4885KDM4E 4401/4885ALDH1A1 1803/4885 |
| US-20180134693-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASES AND CONDITIONS | C1S, SLC10A1, C1R | NOTUM 2085/4885KDM4E 4400/4885ALDH1A1 1801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.